Drug intelligence / Profile preview

Weichangling Capsules

Development stage: Unknown
Lead developer: Yunnan Yongzitang Pharmaceutical
Administration: Oral

Overview

Weichangling Capsules is a traditional Chinese medicine (TCM) formulation developed and manufactured by Yunnan Yongzitang, a subsidiary of Hunan Hansen Pharmaceutical. It is an approved commercial product in China, specifically listed as an exclusive formulation by the company. The medication is intended for oral administration to treat gastrointestinal conditions. As a traditional herbal product, its therapeutic effects are attributed to the synergistic action of its constituent herbs according to TCM principles, rather than a single defined molecular target.

Brand names: Weichangling Capsules胃肠灵胶囊
Other names: Weichangling Jiaonang

Beyond the preview

Go deeper on Weichangling Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weichangling Capsules.

Explore the full profile